Search Within

Chung-Han Lee

Formats
  1. Meeting Abstract (79)
  2. Journal Article (63)
  3. Review (9)
  4. Research Letter (3)
  5. Book Section (2)
  6. Guidelines (1)
Groups
  1. Department of Medicine (157)
  2. Genitourinary Oncology Service (157)
  3. Solid Tumor Oncology Division (157)
  4. Weinberg Fellows (85)
  5. Department of Pathology and Laboratory Medicine (59)
  6. Population Sciences Research Program (59)

More Groups

People
  1. Robert Motzer (109)
  2. Martin Voss (75)
  3. Darren Feldman (55)
  4. Maria Carlo (55)
  5. Abraham Hakimi (42)
  6. Ritesh Kotecha (42)

More People

Years
  1. 2025 (4)
  2. 2024 (9)
  3. 2023 (19)
  4. 2022 (23)
  5. 2021 (20)
  6. 2020 (20)

More Years

Publications
  1. Journal of Clinical Oncology (63)
  2. Annals of Oncology (9)
  3. Clinical Cancer Research (6)
  4. Clinical Genitourinary Cancer (6)
  5. European Urology (5)
  6. European Urology Oncology (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (66)
  2. Oxford University Press (13)
  3. Elsevier Inc. (11)
  4. Nature Publishing Group (11)
  5. American Association for Cancer Research (9)
  6. Elsevier Science, Inc. (7)

More Publishers

Results (157)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A single-arm, phase II study of durvalumab (D) and tremelimumab (T) for relapsed/refractory germ cell tumors (GCT)
    Meeting Abstract

    Funt, S. A.; Knezevic, A.; Freeman, B. A.; Bolos, M.; Martorana, V.; Donoghue, M.; Khan, S.; Singh, H.; Bromberg, M.; Quinlan, C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Germline mutations in hereditary renal cell carcinoma (RCC) genes among 32,240 patients with all cancer types
    Meeting Abstract

    Carlo, M. I.; Schroeder, A.; Mukherjee, S.; Kemel, Y.; Kotecha, R. R.; Lee, C. H.; Shah, N. J.; Feldman, D. R.; Liu, Y. L.; Walsh, M. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial
    Meeting Abstract

    Lee, C. H.; Fitzgerald, K. N.; Voss, M. H.; Carlo, M. I.; Knezevic, A.; Peralta, L.; Chen, Y. B.; Zucker, M.; Lefkowitz, R. A.; Reznik, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma
    Meeting Abstract

    Fitzgerald, K. N.; Kotecha, R. R.; Knezevic, A.; Shapnik, N.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study
    Meeting Abstract

    Lee, C. H.; Gurney, H.; Atduev, V.; Suárez, C.; Climent Duran, M. A.; Pook, D. W.; Tomczak, P.; Barthelemy, P.; Lee, J. L.; Nalbandian, T.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): A single-arm, multicentre, phase 2 trial
    Journal Article

    Albiges, L.; Gurney, H.; Atduev, V.; Suarez, C.; Climent, M. A.; Pook, D.; Tomczak, P.; Barthelemy, P.; Lee, J. L.; Stus, V.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Immunometabolic coevolution defines unique microenvironmental niches in ccRCC
    Journal Article

    Tang, C.; Xie, A. X.; Liu, E. M.; Kuo, F.; Kim, M.; DiNatale, R. G.; Golkaram, M.; Chen, Y. B.; Gupta, S.; Motzer, R. J.; more...
    Cell Metabolism (2023)

    Fulltext@MSK | Save
  • A matching-adjusted indirect comparison of nivolumab plus cabozantinib versus pembrolizumab plus axitinib in patients with advanced renal cell carcinoma
    Journal Article

    McGregor, B.; Geynisman, D. M.; Burotto, M.; Suárez, C.; Bourlon, M. T.; Barata, P. C.; Gulati, S.; Huo, S.; Ejzykowicz, F.; Blum, S. I.; more...
    European Urology Oncology (2023)

    Fulltext@MSK | Save
  • Adjuvant therapy options in renal cell carcinoma — Targeting the metastatic cascade
    Review

    Fitzgerald, K. N.; Motzer, R. J.; Lee, C. H.
    Nature Reviews Urology (2023)

    Fulltext@MSK | Save
  • Progression-free survival after second line of therapy for metastatic clear cell renal cell carcinoma in patients treated with first-line immunotherapy combinations
    Research Letter

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    European Urology (2023)

    Fulltext@MSK | Save